How would you approach incorporating immunotherapy in neoadjuvant treatment for GE junction and Gastric cancer?

Patients with deficient mismatch repair (dMMR) and microsatellite instability high (MSI-H) harbor high tumor mutational burden which tends to have favorable response rates to immune checkpoint inhibitors.

Answer from: Medical Oncologist at Community Practice

Neoadjuvant immunotherapy is a reasonable option for patients with locally advanced dMMR/MSI-H esophagogastric cancer. The recently published GERCOR NEONIPIGA study provides some preliminary data. Among the patients who underwent surgery following neoadjuvant immunotherapy, 59% of patients achieved ...

Comments

Medical Oncologist at Cancer Center Overlook Hospital
In addition, there is data to suggest that giving ...

Please select the option that best describes you:

How would you approach incorporating immunotherapy in neoadjuvant treatment for GE junction and Gastric cancer?

Related Questions